Sail Biomedicines Receives Grants to Fight Malaria by Developing a New Class of RNA Medicines
Summary
Funding from the foundation will support the potential of Sails platform and will enable us to continue to advance our cutting-edge eRNA, with the aim of developing a potent and durable vaccine and monoclonal antibody-based therapy for this deadly, widespread disease," said Guillaume Pfefer, Ph.D., MBA, Chief Executive Officer of Sail Biomedicines and CEO-Partner, Flagship Pioneering.The agreements cover two grant programs. This is based on innovative, translatable, circular RNA that, in preclinical studies, has demonstrated prolonged expression and greater immunogenicity than existing mRNA technology. The aim is to produce a malaria vaccine that drives potent and longer-lasting active immunity, and is potentially more efficacious, than existing options. Sails eRNA technology platform enables prolonged expression of complex biologics, such as fully functional monoclonal antibodies that have the power to provide protection from pathogens - for example, malaria - with greater durability.Together, an enhanced vaccine option for active immunity and monoclonal antibodies for passive immunity could provide an improved range of treatment options to be used in different settings.Sail Biomedicines, a Flagship Pioneering company, is generating tomorrows medicines today through the language of life. By leveraging its rapid prototyping and testing bioplatform, Sail is building a wealth of data, enabling unparalleled use of state-of-the-art AI techniques for the integrative design of RNA medicines with unprecedented performance and broad applicability.